Moffitt Named a Comprehensive Radiopharmaceutical Therapy Center of Excellence by SNMMI
Moffitt Cancer Center has been designated as a Comprehensive Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Institutions designated for this title meet the strict regulatory, training, qualification, experience and performance criteria. This recognition helps assure patients, their families and referring physicians those rigorous procedures are adhered to, leading to appropriate patient selection and outcomes from radiopharmaceutical therapy.
The objective of this program is to ensure patients have reliable access to high-quality radiopharmaceutical therapy by physicians who are expertly trained in nuclear medicine. Moffitt integrates radiopharmaceutical therapy into our pathway of care offering every patient an individualized treatment plan that best meets their needs.
As Florida’s only National Cancer Institute-designated Comprehensive Cancer Center and one of only 29 leading academic centers in the U.S. designated as Comprehensive Radiopharmaceutical Therapy Centers of Excellence by SNMMI, Moffitt is at the very forefront of cancer centers worldwide.
“We are very excited to receive this prestigious designation by the SNMMI. Moffitt’s Radiopharmaceutical Therapy Program treats one of the largest patient populations in the U.S. and is currently the only medical facility in the state of Florida to obtain this designation," said Dr. Ghassan El-Haddad. "Staffed with highly-trained Nuclear Medicine and Interventional Nuclear Oncology healthcare professionals, working side-by-side with clinicians and basic scientists who are bringing radiopharmaceutical therapies from bench-to-bedside, Moffitt is uniquely positioned to advance patient care and contribute to the cure of cancer."